XOMA Royalty (XOMA) Assets Average (2011 - 2026)
XOMA Royalty's (XOMA) quarterly Assets Average came in at $272.3 million in Q1 2026, up 25.47% year-on-year from $217.0 million in Q1 2025, and up 1.62% quarter-over-quarter from $267.9 million in Q4 2025.
XOMA Royalty (XOMA) Assets Average (2011 - 2026) Analysis & Trends
XOMA Royalty has disclosed Assets Average across 16 years of filings, most recently posting $272.3 million for Q1 2026.
- Assets Average for Q1 2026 came in at $272.3 million, up 25.47% year-over-year; the trailing twelve-month figure through Mar 2026 was $272.3 million (up 25.47% YoY), and the FY2025 annual result was $247.0 million, up 8.43% from the prior year.
- Assets Average came in at $272.3 million for Q1 2026 at XOMA Royalty, up from $267.9 million in the prior quarter.
- In the past five years, Assets Average ranged from a high of $272.3 million in Q1 2026 to a low of $124.9 million in Q3 2023.
- The 5-year median for Assets Average is $217.0 million (2025), against an average of $195.1 million.
- Across the five-year window, Assets Average fell 17.25% in 2023 and surged 86.83% in 2024, its largest moves.
- XOMA Royalty's Assets Average stood at $143.3 million in 2022, then rose by 25.09% to $179.2 million in 2023, then rose by 24.06% to $222.3 million in 2024, then rose by 20.52% to $267.9 million in 2025, then rose by 1.62% to $272.3 million in 2026.
- The last three Assets Average figures came in at $272.3 million (Q1 2026), $267.9 million (Q4 2025), and $243.3 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | 33.42 Mn |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | 795.91 Mn |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | 13.04 Mn |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | 1.72 Bn |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | 40.89 Mn |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | 26.03 Mn |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | 10.06 Mn |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | 26.06 Bn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | 660.38 Mn |
| 10 | XOMA Royalty | 5.52 Mn | -60.56 Mn | - | 272.28 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 272.28 Mn |
| Dec 31, 2025 | 267.92 Mn |
| Sep 30, 2025 | 243.30 Mn |
| Jun 30, 2025 | 218.10 Mn |
| Mar 31, 2025 | 217.01 Mn |
| Dec 31, 2024 | 222.31 Mn |
| Sep 30, 2024 | 233.31 Mn |
| Jun 30, 2024 | 231.35 Mn |
| Mar 31, 2024 | 226.86 Mn |
| Dec 31, 2023 | 179.20 Mn |
| Sep 30, 2023 | 124.88 Mn |
| Jun 30, 2023 | 129.66 Mn |
| Mar 31, 2023 | 137.02 Mn |
| Dec 31, 2022 | 143.26 Mn |
| Sep 30, 2022 | 150.18 Mn |
| Jun 30, 2022 | 156.69 Mn |
| Mar 31, 2022 | 162.86 Mn |
| Dec 31, 2021 | 148.53 Mn |
| Sep 30, 2021 | 133.13 Mn |
| Jun 30, 2021 | 127.82 Mn |